Scrip
>>Clinical Trials

Galecto Validates LOXL2 Targeting With Interim Myelofibrosis Phase II Success

30 Sep 2022

• By Ayisha Sharma

The US biotech’s LOXL2 inhibitor candidate has reduced collagen fibrosis of the bone marrow in a small number of Phase II patients, helping validate a historically tricky approach attempted by few.

Row of ticks — Galecto's Drug Is First In Class In The Pipeline • Source: Shutterstock

Galecto Inc.’s GB2064 has shown positive interim efficacy in the Phase IIa MYLOX-1 trial in myelofibrosis, giving weight to the inhibition of LOXL2 as an effective therapeutic strategy for the disease despite the target having little pipeline activity.

MYLOX-1 trial is evaluating twice-daily 1000mg doses of GB2064 in 21 myelofibrosis patients who are ineligible, refractory to or intolerant...